Somewhat Positive News Coverage Somewhat Unlikely to Affect Abbott Laboratories (ABT) Stock Price
Press coverage about Abbott Laboratories (NYSE:ABT) has trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Abbott Laboratories earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned news coverage about the healthcare product maker an impact score of 46.5592927553505 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Abbott Declares 377th Consecutive Quarterly Dividend (finance.yahoo.com)
- Abbott Laboratories Jumps After Boosting Quarterly Dividend (finance.yahoo.com)
- Abbott Laboratories (NYSE:ABT): Does The -66.57% Earnings Decline Make It An Underperformer? (finance.yahoo.com)
- Abbott Laboratories (ABT) Files 10-K for the Fiscal Year Ended on December 31, 2017 (finance.yahoo.com)
- Abbott Laboratories Declares Quarterly Dividend of $0.28 (ABT) (americanbankingnews.com)
Several equities analysts have recently commented on the company. Wells Fargo & Co increased their price objective on Abbott Laboratories from $66.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. Zacks Investment Research cut Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. William Blair upgraded Abbott Laboratories from a “market perform” rating to an “outperform” rating in a report on Thursday, January 25th. Morgan Stanley upgraded Abbott Laboratories from an “equal weight” rating to an “overweight” rating and set a $67.00 target price for the company in a report on Tuesday, January 2nd. Finally, Barclays increased their target price on Abbott Laboratories from $66.00 to $70.00 and gave the company an “overweight” rating in a report on Thursday, January 25th. Eight research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Abbott Laboratories presently has a consensus rating of “Buy” and an average price target of $65.47.
Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.01. Abbott Laboratories had a return on equity of 13.80% and a net margin of 1.74%. The business had revenue of $7.59 billion during the quarter, compared to analysts’ expectations of $7.38 billion. During the same quarter last year, the business posted $0.65 EPS. The business’s revenue was up 42.3% on a year-over-year basis. equities analysts forecast that Abbott Laboratories will post 2.86 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 15th. Shareholders of record on Friday, April 13th will be issued a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 1.86%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 107.69%.
In other Abbott Laboratories news, Chairman Miles D. White sold 276,886 shares of the stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $54.41, for a total value of $15,065,367.26. Following the completion of the sale, the chairman now owns 3,677,913 shares in the company, valued at approximately $200,115,246.33. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Stephen R. Fussell sold 13,313 shares of the stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $62.84, for a total value of $836,588.92. Following the completion of the sale, the executive vice president now owns 152,343 shares of the company’s stock, valued at approximately $9,573,234.12. The disclosure for this sale can be found here. In the last quarter, insiders sold 350,592 shares of company stock valued at $19,426,949. Company insiders own 0.76% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This article was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://theolympiareport.com/2018/02/17/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-abbott-laboratories-abt-stock-price.html.
About Abbott Laboratories
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.